{"gene":"TAFAZZIN","run_date":"2026-06-10T10:51:54","timeline":{"discoveries":[{"year":1996,"finding":"Mutations in the X-linked gene G4.5 (encoding tafazzin proteins produced by alternative splicing) cause Barth syndrome; stop codon mutations interrupt translation of most tafazzin isoforms, establishing G4.5/TAFAZZIN as the disease locus.","method":"Mutation analysis (DNA sequencing identifying stop codon mutations) in Barth syndrome patients","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct mutation identification in multiple patients, replicated across subsequent studies","pmids":["8630491"],"is_preprint":false},{"year":2006,"finding":"Drosophila tafazzin functions as a CoA-independent, acyl-specific phospholipid-lysophospholipid transacylase, catalyzing transfer of acyl groups (preferentially linoleoyl) between cardiolipin and phosphatidylcholine without utilizing CoA or acyl-CoA as substrates; the highest rate is for the phosphatidylcholine–cardiolipin transacylation.","method":"In vitro transacylase assay using baculovirus-expressed Drosophila tafazzin and affinity-purified MBP-tafazzin fusion protein; radiolabeled substrate transfer; substrate specificity profiling","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct in vitro enzymatic reconstitution with purified protein, replicated in multiple subsequent studies","pmids":["17082194"],"is_preprint":false},{"year":2004,"finding":"Yeast taz1Δ (null mutation in the TAFAZZIN homolog) shows reduced total cardiolipin, accumulation of monolyso-CL, loss of unsaturated CL species (C18:1 and C16:1), and increased de novo CL synthesis without upregulation of CL structural genes CRD1 or PGS1, demonstrating tafazzin's role in cardiolipin remodeling and acyl composition.","method":"Yeast genetic model (taz1Δ null mutant); lipid analysis by mass spectrometry/chromatography; growth assays","journal":"Molecular microbiology","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean genetic KO with defined biochemical phenotype, replicated across multiple labs","pmids":["14651618"],"is_preprint":false},{"year":2005,"finding":"Yeast Taz1 (tafazzin ortholog) is an outer mitochondrial membrane protein exposed to the intermembrane space (IMS); its import into mitochondria depends on the TOM receptor Tom5 and the small Tim IMS proteins, but is independent of the SAM complex. TAZ1 deletion destabilizes respiratory chain supercomplexes III2IV2, causing selective release of complex IV monomer and impairing its assembly into supercomplexes.","method":"Subcellular fractionation, protease protection assay, import assays with Tom5/Tim mutants; BN-PAGE supercomplex analysis; radiolabeled subunit import into taz1Δ mitochondria","journal":"Molecular biology of the cell","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple orthogonal methods (fractionation, import assays, BN-PAGE), single lab but rigorous","pmids":["16135531"],"is_preprint":false},{"year":2008,"finding":"Yeast tafazzin (Taz1p) physically assembles into several distinct protein complexes; ATP synthase and AAC2 are identified in separate stable Taz1p complexes by co-immunoprecipitation/MS. The largest Taz1p complex requires both assembled ATP synthase and cardiolipin. Loss of Taz1p alters cristae morphology similar to ATP synthase oligomer mutants without affecting ATP synthase complex assembly.","method":"Co-immunoprecipitation, mass spectrometry (interactome), BN-PAGE, electron microscopy of Δtaz1 mitochondria","journal":"Molecular biology of the cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal co-IP with MS identification plus morphological and biochemical validation, single lab but multiple orthogonal methods","pmids":["18799610"],"is_preprint":false},{"year":2012,"finding":"Tafazzin's transacylation specificity is determined by the physical state (lipid phase) of its substrates rather than intrinsic enzyme acyl selectivity; tetralinoleoyl-cardiolipin forms only under conditions favoring the inverted hexagonal phase, and substantial transacylation occurs only in non-bilayer lipid aggregates. In isolated mitochondria, <1% of lipids participate in transacylation, suggesting tafazzin acts at privileged non-bilayer lipid domains.","method":"In vitro transacylation assay with isolated tafazzin; 31P-NMR characterization of lipid phase; mass spectrometry of molecular species; isolated mitochondria transacylation measurement","journal":"Nature chemical biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstitution with purified enzyme plus structural (NMR) and MS characterization; multiple orthogonal methods in one rigorous study","pmids":["22941046"],"is_preprint":false},{"year":2009,"finding":"Among human tafazzin splice isoforms, only full-length (FL) and the exon-5-deleted (Δ5) isoforms have transacylase activity in vitro and are able to restore normal cardiolipin pattern and respiratory activity in tafazzin-deficient flies; both localize to mitochondria in HeLa cells, but Δ5 is more integrated into the hydrophobic membrane core. Human tafazzin expression in flies generates cardiolipin with a Drosophila (not human) acyl pattern, indicating acyl specificity is not encoded by tafazzin itself.","method":"Expression of isoforms in HeLa/293T and Drosophila; transacylase activity assays; cardiolipin profiling by MS; subcellular fractionation; proteinase K/alkali treatment for topology","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — enzymatic reconstitution, in vivo complementation, topology experiments, MS; multiple orthogonal methods","pmids":["19700766"],"is_preprint":false},{"year":2017,"finding":"The acyl specificity of the tafazzin reaction results from the physical properties (thermodynamic/packing) of the lipid environment rather than intrinsic enzyme-level kinetic specificity; forward and reverse transacylation rates toward equilibrium are similar across different acyl groups, and tafazzin creates an equilibrium distribution of acyl groups.","method":"In vitro transacylation kinetics with yeast tafazzin; comparison of initial rates to equilibrium states across acyl groups; MS quantification of cardiolipin molecular species","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — rigorous in vitro enzymatic analysis with kinetic and thermodynamic dissection, single lab","pmids":["28202545"],"is_preprint":false},{"year":2011,"finding":"Eighteen of 21 tested Barth syndrome missense mutations in tafazzin fail to functionally replace endogenous Taz1p in yeast. Four BTHS mutant tafazzins are degraded by the IMS AAA (i-AAA) protease due to misfolding; paradoxically these assemble into normal-appearing complexes that are inherently unstable and aggregate upon disassembly. Loss of i-AAA protease partially rescues mutant function.","method":"Yeast BTHS mutant panel; functional complementation assays; BN-PAGE complex analysis; i-AAA protease deletion epistasis; protein stability assays","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — systematic panel of 21 mutations with multiple orthogonal functional and biochemical readouts, single lab","pmids":["21300850"],"is_preprint":false},{"year":2015,"finding":"TAZ/tafazzin-mediated cardiolipin remodeling is selectively required for the initiation of mitophagy (mitophagosome biogenesis) but not for other autophagic processes; TAZ deficiency in mouse embryonic fibroblasts causes defective mitophagy, impaired oxidative phosphorylation, and severe oxidative stress.","method":"Doxycycline-inducible Taz knockdown in primary MEFs; autophagy flux assays; mitophagy-specific assays; oxidative phosphorylation measurements","journal":"Autophagy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean inducible KD with specific mitophagy phenotype readout, single lab, two methods","pmids":["25919711"],"is_preprint":false},{"year":2013,"finding":"Deletion of the CL-specific phospholipase Cld1 rescues growth, lifespan, and respiratory defects of the yeast taz1Δ mutant, demonstrating that the decreased CL/MLCL ratio (not deficiency in unsaturated CL) is the primary cause of physiological defects in tafazzin-deficient cells.","method":"Genetic epistasis (cld1Δ taz1Δ double mutant); growth and lifespan assays; respiratory measurements; lipid analysis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean genetic epistasis with defined biochemical and physiological phenotypes, multiple readouts","pmids":["24318983"],"is_preprint":false},{"year":2008,"finding":"Loss of tafazzin (taz1Δ) in yeast causes increased reactive oxygen species (protein carbonylation) specifically during respiratory growth on ethanol; supplementation with oleic acid rescues ethanol sensitivity and reduces oxidative stress in taz1Δ but not crd1Δ, suggesting oleoyl-CL or oleoyl-MLCL mediates this protection.","method":"Yeast taz1Δ and crd1Δ mutants; protein carbonylation assay (ROS marker); growth assays; oleic acid supplementation rescue","journal":"Molecular microbiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO with defined biochemical phenotype, rescue experiment, single lab","pmids":["18430085"],"is_preprint":false},{"year":2014,"finding":"Aim24, an inner mitochondrial membrane protein interacting with the MICOS complex, is required to maintain tafazzin levels; loss of Aim24 drastically reduces tafazzin protein and alters cardiolipin composition similarly to tafazzin mutants, placing tafazzin functionally downstream of the Aim24–MICOS axis.","method":"Co-immunoprecipitation (Aim24–MICOS interaction); protein level analysis; cardiolipin composition by MS in aim24 mutants","journal":"eLife","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP plus lipid phenotyping, single lab, two orthogonal methods","pmids":["24714493"],"is_preprint":false},{"year":2017,"finding":"Two distinct peptide sequences within human tafazzin independently direct the protein to mitochondria; these mitochondrial localization signals are not within predicted enzymatic clefts, implying some BTHS mutations may disrupt localization independently of transacylase activity.","method":"Sequential TAZ peptide–eGFP fusion protein expression in H9c2 cells; confocal microscopy co-localization with organellar markers; CRISPR TAZ knockout cell lines","journal":"Journal of molecular and cellular cardiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct localization by live-cell imaging with functional validation in KO background, single lab","pmids":["29129703"],"is_preprint":false},{"year":2018,"finding":"Tafazzin deficiency causes a substantial decrease in plasmenylcholine (plasmalogen) in the heart, in addition to reduced CL and accumulated MLCL; purified tafazzin catalyzes transacylation between lyso-plasmenylcholine/plasmenylcholine and CL/MLCL, establishing plasmenylcholine as a tafazzin substrate for CL remodeling.","method":"31P-NMR lipid quantification in TAZ-KD mouse hearts; in vitro transacylation assay with purified tafazzin and plasmalogen substrates; Western blot for Far1","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with purified enzyme plus in vivo lipid phenotyping by NMR, single lab, two orthogonal methods","pmids":["29557170"],"is_preprint":false},{"year":2020,"finding":"Tafazzin deficiency in mouse hearts causes deficiencies in mitochondrial CoA and shifts in the acyl-CoA profile that impair fatty acid and pyruvate oxidation (40–60% lower); exogenous CoA partially rescues these oxidation defects, implicating dysregulation of CoA-dependent intermediary metabolism rather than primary respiratory chain defects as the bioenergetic consequence of tafazzin deficiency.","method":"Taz-shRNA knockdown mice; mitochondrial substrate oxidation assays; CoA metabolite profiling by LC-MS; CoA supplementation rescue experiments","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean KD model, substrate oxidation assays, metabolomics, rescue experiment; single lab","pmids":["32665401"],"is_preprint":false},{"year":2019,"finding":"Tafazzin (TAZ) is necessary for growth and viability of AML cells (identified by CRISPR screen); TAZ inhibition reduces AML stemness and increases differentiation in vitro and in vivo by decreasing cardiolipin and altering global phospholipid levels (including phosphatidylserine), which modulates toll-like receptor (TLR) signaling.","method":"CRISPR screen; genetic TAZ inhibition in AML cells in vitro and xenograft in vivo; phospholipid profiling; TLR signaling pathway analysis","journal":"Cell stem cell","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — CRISPR KO with defined cellular phenotype plus pathway placement via lipid profiling and TLR signaling, single lab","pmids":["30930145"],"is_preprint":false},{"year":2015,"finding":"Mouse tafazzin (Taz) is required for male germ cell meiosis; Taz knockout chimera testes show disruption of spermatocyte progression past the pachytene stage, elevated DNA double-strand damage, and increased endogenous retrotransposon activity, revealing a role for tafazzin in maintaining genome integrity during meiosis.","method":"Taz knockout mouse chimeras; histological analysis of testes; DNA damage markers (γH2AX); retrotransposon expression; in vitro germ cell differentiation from KO ES cells","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO with defined meiotic phenotype and molecular markers, single lab","pmids":["26114544"],"is_preprint":false},{"year":2013,"finding":"Tafazzin knockdown in lymphoblasts from Barth syndrome patients destabilizes the respiratory supercomplex I+III2+IVn (respirasome) and reduces individual complexes I and IV, complex V, and supercomplexes I+III and III+IV; complex III amount and complex II are unaffected. Mitochondrial mass increases as a compensatory response, and the type II (mitochondrial) apoptosis pathway is blocked because mitochondria cannot bind active caspase-8.","method":"Immortalized patient lymphoblasts; BN-PAGE supercomplex analysis; electron microscopy; citrate synthase activity; flow cytometry for apoptosis/caspase-8 binding","journal":"Biochimica et biophysica acta","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — patient-derived cells, multiple orthogonal methods; single lab","pmids":["23523468"],"is_preprint":false},{"year":2008,"finding":"Distinct effects of tafazzin deletion on mitochondrial ultrastructure depend on cellular differentiation state: tafazzin deficiency affects cardiolipin in all mitochondria, but significant structural alterations (inner membrane remodeling and aggregation) occur only after specific differentiation, as shown in cardiomyocytes vs. embryonic stem cells and in different Drosophila tissues.","method":"Electron tomography of tafazzin-deleted mouse cardiomyocytes, embryonic stem cells, and Drosophila tissues; cardiolipin profiling","journal":"Mitochondrion","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — electron tomography (structural method) with comparative cellular context; single lab","pmids":["19114128"],"is_preprint":false},{"year":2022,"finding":"In vivo treatment with the mitochondria-targeted peptide SS-31 improves mitochondrial respiratory capacity and promotes supercomplex organization in tafazzin-knockdown mouse cardiac mitochondria without affecting the MLCL/CL ratio, suggesting SS-31 acts on respiratory chain function independently of direct CL modification.","method":"In vivo SS-31 administration in TazKD mice; MALDI-TOF/MS lipid profiling; mitochondrial respiration assays; BN-PAGE supercomplex analysis","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo intervention with functional and lipid readouts; single lab","pmids":["36400945"],"is_preprint":false},{"year":2019,"finding":"Tafazzin deletion in C2C12 myoblasts (TAZ-KO) causes accumulation of monolyso-CL, decreased mitochondrial respiration, increased mitochondrial ROS, and impaired myocyte differentiation, linking defective CL remodeling to skeletal myoblast differentiation defects.","method":"CRISPR-generated stable tafazzin KO C2C12 cell line; cardiolipin profiling; mitochondrial respiration (Seahorse); ROS measurement; differentiation assays","journal":"Biochimica et biophysica acta. Molecular and cell biology of lipids","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — CRISPR KO with defined biochemical and differentiation phenotypes; single lab","pmids":["29694924"],"is_preprint":false},{"year":2022,"finding":"TAFAZZIN-deficient neutrophil progenitors (in KO mice and ER-Hoxb8 system) show increased sensitivity to ER stress-mediated apoptosis, with transcriptomic upregulation of ER stress markers, providing a mechanistic link between tafazzin loss and neutrophil vulnerability.","method":"TAFAZZIN KO mice; ER-Hoxb8 conditional immortalization system; transcriptomic analysis; apoptosis assays with ER stress inducers","journal":"Blood advances","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — two model systems, transcriptomics plus functional apoptosis assay; single lab","pmids":["34979560"],"is_preprint":false}],"current_model":"Tafazzin is a mitochondrial CoA-independent phospholipid-lysophospholipid transacylase that remodels cardiolipin by exchanging acyl chains between phospholipids (preferentially phosphatidylcholine and cardiolipin), with acyl specificity dictated by the physical properties (phase state) of non-bilayer lipid domains rather than by intrinsic enzymatic selectivity; it localizes to the mitochondrial membrane via two distinct targeting peptides, assembles into complexes with ATP synthase and the adenine nucleotide carrier, and its loss causes accumulation of monolyso-cardiolipin, destabilization of respiratory supercomplexes, impaired oxidative phosphorylation, increased ROS, defective mitophagy, and—in vivo—cardiomyopathy, skeletal myopathy, and neutropenia characteristic of Barth syndrome."},"narrative":{"mechanistic_narrative":"Tafazzin is a mitochondrial CoA-independent phospholipid–lysophospholipid transacylase that remodels cardiolipin, and its loss causes the X-linked disorder Barth syndrome [PMID:8630491, PMID:17082194]. The enzyme transfers acyl chains between phospholipids—preferentially exchanging linoleoyl groups between phosphatidylcholine and cardiolipin, and also drawing on plasmenylcholine as a donor—without using CoA or acyl-CoA [PMID:17082194, PMID:29557170]. Rather than encoding intrinsic acyl selectivity, tafazzin generates an equilibrium distribution of acyl species whose final composition is dictated by the physical/phase state of its lipid substrates, acting preferentially at non-bilayer lipid domains [PMID:22941046, PMID:28202545]; consistent with this, human tafazzin expressed in flies produces a Drosophila acyl pattern [PMID:19700766]. Loss of tafazzin reduces total cardiolipin and causes accumulation of monolyso-cardiolipin, and it is this decreased CL/MLCL ratio—not the deficit in unsaturated CL—that drives the physiological defects, since deleting the CL-specific phospholipase Cld1 rescues taz-null cells [PMID:14651618, PMID:24318983]. Tafazzin localizes to mitochondria via two independent targeting peptides and is imported through the TOM/small-Tim pathway to face the intermembrane space [PMID:16135531, PMID:29129703]; it assembles into distinct complexes with ATP synthase and the adenine nucleotide carrier AAC2 [PMID:18799610]. Functionally, tafazzin remodeling is required to stabilize respiratory chain supercomplexes (respirasomes), and its loss destabilizes complex IV-containing supercomplexes, impairs oxidative phosphorylation, increases ROS, and disrupts cristae architecture in a differentiation-dependent manner [PMID:16135531, PMID:23523468, PMID:19114128]. Downstream consequences include defective mitophagy initiation, dysregulated CoA-dependent fatty acid and pyruvate oxidation, and impaired myocyte differentiation [PMID:25919711, PMID:32665401, PMID:29694924]. Disease-relevant phenotypes trace to these defects: most Barth syndrome missense mutants fail to function and are degraded by the i-AAA protease [PMID:21300850], and tafazzin loss confers cardiac, skeletal-muscle, and neutrophil vulnerabilities, the last via heightened sensitivity to ER stress-mediated apoptosis [PMID:29694924, PMID:34979560].","teleology":[{"year":1996,"claim":"Established TAFAZZIN (G4.5) as the genetic cause of a human disease, defining the disease locus before any molecular function was known.","evidence":"Mutation analysis identifying stop-codon mutations in Barth syndrome patients","pmids":["8630491"],"confidence":"High","gaps":["Did not reveal the biochemical function of the encoded protein","Functional consequences of individual splice isoforms unresolved"]},{"year":2004,"claim":"Linked tafazzin to cardiolipin biology by showing a null mutant accumulates monolyso-CL and loses unsaturated CL species, defining its role in CL acyl remodeling rather than de novo synthesis.","evidence":"Yeast taz1Δ null mutant with MS lipid profiling and growth assays","pmids":["14651618"],"confidence":"High","gaps":["Did not establish the enzymatic mechanism directly","Did not determine acyl-chain donor specificity"]},{"year":2005,"claim":"Located tafazzin topologically and connected its loss to respiratory supercomplex integrity, the first link between CL remodeling and OXPHOS assembly.","evidence":"Subcellular fractionation, protease protection, TOM/Tim import assays, and BN-PAGE supercomplex analysis in yeast","pmids":["16135531"],"confidence":"High","gaps":["Mechanism by which CL remodeling stabilizes supercomplexes not defined","Did not address mammalian topology"]},{"year":2006,"claim":"Defined the enzymatic activity directly: tafazzin is a CoA-independent, acyl-specific phospholipid–lysophospholipid transacylase favoring PC–CL transfer.","evidence":"In vitro transacylase assay with purified baculovirus-expressed Drosophila tafazzin and radiolabeled substrate transfer","pmids":["17082194"],"confidence":"High","gaps":["Source of acyl-chain specificity not yet explained","Did not test plasmalogen or other phospholipid donors"]},{"year":2008,"claim":"Mapped tafazzin into discrete physical complexes with ATP synthase and AAC2 and linked its loss to cristae morphology, positioning it within the mitochondrial membrane architecture machinery.","evidence":"Co-IP/MS interactome, BN-PAGE, and electron microscopy of Δtaz1 yeast mitochondria","pmids":["18799610"],"confidence":"High","gaps":["Stoichiometry and function of each complex not resolved","Whether complexes reflect catalytic substrate channeling unknown"]},{"year":2008,"claim":"Connected tafazzin loss to oxidative stress and identified a specific protective lipid species, refining which CL/MLCL derivatives matter physiologically.","evidence":"Protein carbonylation in taz1Δ vs crd1Δ yeast with oleic-acid rescue","pmids":["18430085"],"confidence":"Medium","gaps":["Direct demonstration that oleoyl-CL/MLCL is the protective species not shown","Relevance to mammalian ROS phenotype untested"]},{"year":2009,"claim":"Resolved which human splice isoforms are catalytically competent and showed acyl specificity is host-encoded, not enzyme-intrinsic.","evidence":"Isoform expression in HeLa/293T and Drosophila, transacylase assays, CL profiling, and topology experiments","pmids":["19700766"],"confidence":"High","gaps":["Why exon-5 deletion alters membrane integration mechanistically unclear","Physiological roles of inactive isoforms unknown"]},{"year":2011,"claim":"Explained how Barth missense mutations cause disease: most are non-functional, and a subset is degraded by the i-AAA protease due to misfolding.","evidence":"Systematic yeast complementation of 21 BTHS mutants with BN-PAGE and i-AAA protease epistasis","pmids":["21300850"],"confidence":"High","gaps":["Structural basis of misfolding not defined","Whether the same degradation pathway operates in human cells untested"]},{"year":2012,"claim":"Provided the physical explanation for acyl specificity—lipid phase state, not enzyme kinetics, drives tetralinoleoyl-CL formation at non-bilayer domains.","evidence":"In vitro transacylation with 31P-NMR lipid-phase characterization and MS species analysis","pmids":["22941046"],"confidence":"High","gaps":["Identity of the privileged non-bilayer domains in vivo not defined","How tafazzin is recruited to these domains unknown"]},{"year":2013,"claim":"Demonstrated genetically that the low CL/MLCL ratio, not loss of unsaturated CL, is the proximal cause of physiological defects.","evidence":"cld1Δ taz1Δ double-mutant epistasis with growth, lifespan, respiration, and lipid readouts in yeast","pmids":["24318983"],"confidence":"High","gaps":["Molecular basis of MLCL toxicity not defined","Whether Cld1 deletion rescues mammalian phenotypes untested"]},{"year":2013,"claim":"Quantified the supercomplex defect in patient cells and linked tafazzin loss to a block in mitochondrial apoptosis via impaired caspase-8 binding.","evidence":"BN-PAGE, EM, citrate synthase, and flow cytometry in Barth patient lymphoblasts","pmids":["23523468"],"confidence":"Medium","gaps":["Mechanism connecting CL remodeling to caspase-8 recruitment unresolved","Single lab, patient-derived cells only"]},{"year":2014,"claim":"Placed tafazzin downstream of the Aim24–MICOS axis, identifying an upstream determinant of tafazzin protein levels.","evidence":"Co-IP and CL profiling in aim24 mutant yeast","pmids":["24714493"],"confidence":"Medium","gaps":["How Aim24/MICOS stabilizes tafazzin mechanistically unknown","No mammalian validation"]},{"year":2015,"claim":"Identified mitophagy initiation as a selective process requiring CL remodeling, distinguishing it from bulk autophagy.","evidence":"Inducible Taz knockdown in primary MEFs with autophagy/mitophagy flux and OXPHOS assays","pmids":["25919711"],"confidence":"Medium","gaps":["Molecular role of remodeled CL in mitophagosome biogenesis not defined","Single lab, two methods"]},{"year":2015,"claim":"Revealed a non-bioenergetic role in male meiosis and genome integrity, broadening tafazzin's physiological reach.","evidence":"Taz KO mouse chimeras with testis histology, γH2AX, retrotransposon expression, and KO ES germ-cell differentiation","pmids":["26114544"],"confidence":"Medium","gaps":["Mechanistic link between CL remodeling and meiotic genome stability unclear","Whether the defect is mitochondrial-autonomous unknown"]},{"year":2017,"claim":"Established quantitatively that tafazzin drives acyl groups toward thermodynamic equilibrium rather than imposing kinetic selectivity.","evidence":"In vitro kinetic and equilibrium analysis with yeast tafazzin and MS quantification","pmids":["28202545"],"confidence":"High","gaps":["How equilibrium tuning produces tissue-specific CL patterns in vivo unresolved"]},{"year":2017,"claim":"Mapped two independent mitochondrial targeting peptides outside the catalytic cleft, implying some BTHS mutations may act by disrupting localization rather than catalysis.","evidence":"TAZ peptide–eGFP fusions and confocal co-localization in H9c2 cells with CRISPR TAZ-KO controls","pmids":["29129703"],"confidence":"Medium","gaps":["Which disease mutations disrupt localization not directly tested","Relative contribution of each peptide unclear"]},{"year":2018,"claim":"Expanded the substrate repertoire by showing plasmenylcholine is a tafazzin donor for CL remodeling and is depleted in deficient hearts.","evidence":"31P-NMR lipid quantification in TAZ-KD mouse hearts and in vitro transacylation with purified enzyme and plasmalogen substrates","pmids":["29557170"],"confidence":"High","gaps":["Physiological significance of plasmalogen depletion in Barth syndrome unresolved"]},{"year":2019,"claim":"Identified tafazzin as a vulnerability in acute myeloid leukemia, linking CL/phospholipid remodeling to stemness via TLR signaling.","evidence":"CRISPR screen and genetic TAZ inhibition in AML cells and xenografts with phospholipid and TLR pathway analysis","pmids":["30930145"],"confidence":"Medium","gaps":["Direct mechanism connecting phosphatidylserine changes to TLR signaling not fully defined","Specificity to AML versus other cancers untested"]},{"year":2019,"claim":"Tied CL remodeling defects to skeletal-muscle differentiation, modeling the myopathy component of Barth syndrome.","evidence":"CRISPR TAZ-KO C2C12 myoblasts with CL profiling, Seahorse respiration, ROS, and differentiation assays","pmids":["29694924"],"confidence":"Medium","gaps":["Mechanism linking respiratory defect to differentiation block unclear","Single cell-line model"]},{"year":2020,"claim":"Reframed the bioenergetic defect as dysregulation of CoA-dependent intermediary metabolism, partially rescuable by exogenous CoA.","evidence":"Taz-shRNA knockdown mice with substrate oxidation assays, CoA metabolomics, and CoA supplementation","pmids":["32665401"],"confidence":"Medium","gaps":["How CL/MLCL imbalance lowers mitochondrial CoA mechanistically unknown","Relative contribution of CoA defect vs supercomplex defect unresolved"]},{"year":2022,"claim":"Provided a candidate therapeutic mechanism: SS-31 restores respiratory function and supercomplex organization independently of correcting the MLCL/CL ratio.","evidence":"In vivo SS-31 in TazKD mice with MALDI lipid profiling, respiration, and BN-PAGE","pmids":["36400945"],"confidence":"Medium","gaps":["Molecular target of SS-31 in this context not defined","Durability and disease-modifying effect untested"]},{"year":2022,"claim":"Explained neutropenia in Barth syndrome by linking tafazzin loss to ER stress-mediated apoptosis in neutrophil progenitors.","evidence":"TAFAZZIN KO mice and ER-Hoxb8 system with transcriptomics and ER stress apoptosis assays","pmids":["34979560"],"confidence":"Medium","gaps":["Connection between mitochondrial CL defect and ER stress signaling not defined","Whether intervention rescues neutrophil numbers untested"]},{"year":null,"claim":"How tafazzin is recruited to specific non-bilayer lipid domains in vivo, and how a single equilibrium-driving transacylase produces tissue-specific cardiolipin signatures and the diverse downstream phenotypes (mitophagy, CoA metabolism, ER stress), remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structure of human tafazzin bound to substrate","Mechanism linking CL/MLCL ratio to supercomplex stabilization, mitophagy, and apoptosis not unified","In vivo determinants of acyl-chain specificity per tissue unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[1,5,6,7,14]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[1,14]},{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[1,5,14]}],"localization":[{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[3,6,13]},{"term_id":"GO:0005635","term_label":"nuclear envelope","supporting_discovery_ids":[3]}],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[2,14,15]},{"term_id":"R-HSA-1852241","term_label":"Organelle biogenesis and maintenance","supporting_discovery_ids":[3,4,18,19]},{"term_id":"R-HSA-9612973","term_label":"Autophagy","supporting_discovery_ids":[9]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[0,8]}],"complexes":["ATP synthase complex","AAC2 (adenine nucleotide carrier) complex"],"partners":["ATP SYNTHASE","AAC2","AIM24","MICOS"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q16635","full_name":"Tafazzin","aliases":["Protein G4.5"],"length_aa":262,"mass_kda":30.2,"function":"Acyltransferase required to remodel newly synthesized phospholipid cardiolipin (1',3'-bis-[1,2-diacyl-sn-glycero-3-phospho]-glycerol or CL), a key component of the mitochondrial inner membrane, with tissue specific acyl chains necessary for adequate mitochondrial function (PubMed:12930833, PubMed:19164547, PubMed:19700766, PubMed:26908608, PubMed:33096711). Its role in cellular physiology is to improve mitochondrial performance (PubMed:32234310). CL is critical for the coassembly of lipids and proteins in mitochondrial membranes, for instance, remodeling of the acyl groups of CL in the mitochondrial inner membrane affects the assembly and stability of respiratory chain complex IV and its supercomplex forms (By similarity). Catalyzes the transacylation between phospholipids and lysophospholipids, with the highest rate being between phosphatidylcholine (1,2-diacyl-sn-glycero-3-phosphocholine or PC) and CL. Catalyzes both 1-acyl-sn-glycero-3-phosphocholine (lysophosphatidylcholine or LPC) reacylation and PC-CL transacylation, that means, it exchanges acyl groups between CL and PC by a combination of forward and reverse transacylations. Also catalyzes transacylations between other phospholipids such as phosphatidylethanolamine (1,2-diacyl-sn-glycero-3-phosphoethanolamine or PE) and CL, between PC and PE, and between PC and phosphatidate (1,2-diacyl-sn-glycero-3-phosphate or PA), although at lower rate. Not regiospecific, it transfers acyl groups into any of the sn-1 and sn-2 positions of the monolysocardiolipin (MLCL), which is an important prerequisite for uniformity and symmetry in CL acyl distribution. Cannot transacylate dilysocardiolipin (DLCL), thus, the role of MLCL is limited to that of an acyl acceptor. CoA-independent, it can reshuffle molecular species within a single phospholipid class. Redistributes fatty acids between MLCL, CL, and other lipids, which prolongs the half-life of CL. Its action is completely reversible, which allows for cyclic changes, such as fission and fusion or bending and flattening of the membrane. Hence, by contributing to the flexibility of the lipid composition, it plays an important role in the dynamics of mitochondria membranes. Essential for the final stage of spermatogenesis, spermatid individualization (By similarity). Required for the initiation of mitophagy (PubMed:33096711). Required to ensure progression of spermatocytes through meiosis (By similarity). Exon 7 of human tafazzin is essential for catalysis (PubMed:19700766) Catalyzes the transacylation between lysophosphatidate (such as 1-acyl-sn-glycero-3-phosphate) and phosphatidylglycerol (1,2-diacyl-sn-glycero-3-phospho-(1'-sn-glycerol)) (PubMed:19700766). Contributes to cardiolipin (1',3'-bis-[1,2-diacyl-sn-glycero-3-phospho]-glycerol or CL) remodeling (PubMed:12930833, PubMed:19700766) Catalyzes the transacylation between lysophospholipids and phospholipids, and plays a fundamental role in cardiolipin (1',3'-bis-[1,2-diacyl-sn-glycero-3-phospho]-glycerol or CL) metabolism and remodeling Catalytically inactive Catalytically inactive","subcellular_location":"Cytoplasm","url":"https://www.uniprot.org/uniprotkb/Q16635/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/TAFAZZIN","classification":"Not Classified","n_dependent_lines":458,"n_total_lines":1208,"dependency_fraction":0.3791390728476821},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/TAFAZZIN","total_profiled":1310},"omim":[{"mim_id":"620119","title":"LONG NONCODING RNA CRYBG3","url":"https://www.omim.org/entry/620119"},{"mim_id":"607392","title":"WW DOMAIN-CONTAINING TRANSCRIPTION REGULATOR 1; WWTR1","url":"https://www.omim.org/entry/607392"},{"mim_id":"302060","title":"BARTH SYNDROME; BTHS","url":"https://www.omim.org/entry/302060"},{"mim_id":"300394","title":"TAFAZZIN, PHOSPHOLIPID-LYSOPHOSPHOLIPID TRANSACYLASE; TAFAZZIN","url":"https://www.omim.org/entry/300394"},{"mim_id":"250950","title":"3-@METHYLGLUTACONIC ACIDURIA, TYPE I; MGCA1","url":"https://www.omim.org/entry/250950"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/TAFAZZIN"},"hgnc":{"alias_symbol":["BTHS","G4.5","TAZ1"],"prev_symbol":["CMD3A","EFE2","EFE","TAZ"]},"alphafold":{"accession":"Q16635","domains":[{"cath_id":"3.40.1130.10","chopping":"42-78_94-125_156-286","consensus_level":"high","plddt":94.1075,"start":42,"end":286}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q16635","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q16635-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q16635-F1-predicted_aligned_error_v6.png","plddt_mean":94.88},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=TAFAZZIN","jax_strain_url":"https://www.jax.org/strain/search?query=TAFAZZIN"},"sequence":{"accession":"Q16635","fasta_url":"https://rest.uniprot.org/uniprotkb/Q16635.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q16635/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q16635"}},"corpus_meta":[{"pmid":"8630491","id":"PMC_8630491","title":"A novel X-linked gene, G4.5. is responsible for Barth syndrome.","date":"1996","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/8630491","citation_count":594,"is_preprint":false},{"pmid":"17082194","id":"PMC_17082194","title":"The enzymatic function of tafazzin.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17082194","citation_count":278,"is_preprint":false},{"pmid":"9572143","id":"PMC_9572143","title":"Fission yeast Taz1 protein is required for meiotic telomere clustering and recombination.","date":"1998","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/9572143","citation_count":235,"is_preprint":false},{"pmid":"11676925","id":"PMC_11676925","title":"spRap1 and spRif1, recruited to telomeres by Taz1, are essential for telomere function in fission yeast.","date":"2001","source":"Current biology : CB","url":"https://pubmed.ncbi.nlm.nih.gov/11676925","citation_count":234,"is_preprint":false},{"pmid":"16598261","id":"PMC_16598261","title":"Semi-conservative DNA replication through telomeres requires Taz1.","date":"2006","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/16598261","citation_count":217,"is_preprint":false},{"pmid":"16243027","id":"PMC_16243027","title":"Telomere binding protein Taz1 establishes Swi6 heterochromatin independently of RNAi at telomeres.","date":"2005","source":"Current biology : CB","url":"https://pubmed.ncbi.nlm.nih.gov/16243027","citation_count":184,"is_preprint":false},{"pmid":"14651618","id":"PMC_14651618","title":"Aberrant cardiolipin metabolism in the yeast taz1 mutant: a model for Barth syndrome.","date":"2004","source":"Molecular microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/14651618","citation_count":176,"is_preprint":false},{"pmid":"16135531","id":"PMC_16135531","title":"Taz1, an outer mitochondrial membrane protein, affects stability and assembly of inner membrane protein complexes: implications for Barth Syndrome.","date":"2005","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/16135531","citation_count":174,"is_preprint":false},{"pmid":"9382096","id":"PMC_9382096","title":"The X-linked gene G4.5 is responsible for different infantile dilated cardiomyopathies.","date":"1997","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/9382096","citation_count":172,"is_preprint":false},{"pmid":"23523468","id":"PMC_23523468","title":"Barth syndrome: cellular compensation of mitochondrial dysfunction and apoptosis inhibition due to changes in cardiolipin remodeling linked to tafazzin (TAZ) gene mutation.","date":"2013","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/23523468","citation_count":146,"is_preprint":false},{"pmid":"11172711","id":"PMC_11172711","title":"The fission yeast Taz1 protein protects chromosomes from Ku-dependent end-to-end fusions.","date":"2001","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/11172711","citation_count":141,"is_preprint":false},{"pmid":"19619503","id":"PMC_19619503","title":"The enigmatic role of tafazzin in cardiolipin metabolism.","date":"2009","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/19619503","citation_count":131,"is_preprint":false},{"pmid":"22941046","id":"PMC_22941046","title":"The physical state of lipid substrates provides transacylation specificity for tafazzin.","date":"2012","source":"Nature chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/22941046","citation_count":113,"is_preprint":false},{"pmid":"16096639","id":"PMC_16096639","title":"Taz1, Rap1 and Rif1 act both interdependently and independently to maintain telomeres.","date":"2005","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/16096639","citation_count":101,"is_preprint":false},{"pmid":"25919711","id":"PMC_25919711","title":"Cardiolipin remodeling by TAZ/tafazzin is selectively required for the initiation of mitophagy.","date":"2015","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/25919711","citation_count":101,"is_preprint":false},{"pmid":"12468278","id":"PMC_12468278","title":"Mutation analysis of the G4.5 gene in patients with isolated left ventricular noncompaction.","date":"2002","source":"Molecular genetics and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/12468278","citation_count":100,"is_preprint":false},{"pmid":"14594809","id":"PMC_14594809","title":"Interaction of the TAZ1 domain of the CREB-binding protein with the activation domain of CITED2: regulation by competition between intrinsically unstructured ligands for non-identical binding sites.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/14594809","citation_count":97,"is_preprint":false},{"pmid":"21091282","id":"PMC_21091282","title":"Characterization of a transgenic short hairpin RNA-induced murine model of Tafazzin deficiency.","date":"2011","source":"Human gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/21091282","citation_count":97,"is_preprint":false},{"pmid":"12368491","id":"PMC_12368491","title":"Silencing of the tapetum-specific zinc finger gene TAZ1 causes premature degeneration of tapetum and pollen abortion in petunia.","date":"2002","source":"The Plant cell","url":"https://pubmed.ncbi.nlm.nih.gov/12368491","citation_count":88,"is_preprint":false},{"pmid":"18799610","id":"PMC_18799610","title":"The cardiolipin transacylase, tafazzin, associates with two distinct respiratory components providing insight into Barth syndrome.","date":"2008","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/18799610","citation_count":88,"is_preprint":false},{"pmid":"14764526","id":"PMC_14764526","title":"Neutrophils in Barth syndrome (BTHS) avidly bind annexin-V in the absence of apoptosis.","date":"2004","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/14764526","citation_count":84,"is_preprint":false},{"pmid":"18430085","id":"PMC_18430085","title":"Loss of tafazzin in yeast leads to increased oxidative stress during respiratory growth.","date":"2008","source":"Molecular microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/18430085","citation_count":78,"is_preprint":false},{"pmid":"15641773","id":"PMC_15641773","title":"CBP/p300 TAZ1 domain forms a structured scaffold for ligand binding.","date":"2005","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15641773","citation_count":71,"is_preprint":false},{"pmid":"8393937","id":"PMC_8393937","title":"Ligand binding to the receptor domain regulates the ratio of kinase to phosphatase activities of the signaling domain of the hybrid Escherichia coli transmembrane receptor, Taz1.","date":"1993","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/8393937","citation_count":71,"is_preprint":false},{"pmid":"24714493","id":"PMC_24714493","title":"Aim24 and MICOS modulate respiratory function, tafazzin-related cardiolipin modification and mitochondrial architecture.","date":"2014","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/24714493","citation_count":69,"is_preprint":false},{"pmid":"15588229","id":"PMC_15588229","title":"Ypr140wp, 'the yeast tafazzin', displays a mitochondrial lysophosphatidylcholine (lyso-PC) acyltransferase activity related to triacylglycerol and mitochondrial lipid synthesis.","date":"2005","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/15588229","citation_count":69,"is_preprint":false},{"pmid":"8389884","id":"PMC_8389884","title":"Requirement of both kinase and phosphatase activities of an Escherichia coli receptor (Taz1) for ligand-dependent signal transduction.","date":"1993","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/8389884","citation_count":68,"is_preprint":false},{"pmid":"12620220","id":"PMC_12620220","title":"The telomere protein Taz1 is required to prevent and repair genomic DNA breaks.","date":"2003","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/12620220","citation_count":68,"is_preprint":false},{"pmid":"16794186","id":"PMC_16794186","title":"A zebrafish model of human Barth syndrome reveals the essential role of tafazzin in cardiac development and function.","date":"2006","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/16794186","citation_count":68,"is_preprint":false},{"pmid":"16407326","id":"PMC_16407326","title":"Evolutionary-conserved telomere-linked helicase genes of fission yeast are repressed by silencing factors, RNAi components and the telomere-binding protein Taz1.","date":"2006","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/16407326","citation_count":66,"is_preprint":false},{"pmid":"10484795","id":"PMC_10484795","title":"Genetic analysis of the G4.5 gene in families with suspected Barth syndrome.","date":"1999","source":"The Journal of pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/10484795","citation_count":65,"is_preprint":false},{"pmid":"22987637","id":"PMC_22987637","title":"Telomere-binding protein Taz1 controls global replication timing through its localization near late replication origins in fission yeast.","date":"2012","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/22987637","citation_count":62,"is_preprint":false},{"pmid":"19114128","id":"PMC_19114128","title":"Distinct effects of tafazzin deletion in differentiated and undifferentiated mitochondria.","date":"2008","source":"Mitochondrion","url":"https://pubmed.ncbi.nlm.nih.gov/19114128","citation_count":61,"is_preprint":false},{"pmid":"15172004","id":"PMC_15172004","title":"Isolated left ventricular noncompaction is rarely caused by mutations in G4.5, alpha-dystrobrevin and FK Binding Protein-12.","date":"2004","source":"Molecular genetics and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/15172004","citation_count":59,"is_preprint":false},{"pmid":"11896212","id":"PMC_11896212","title":"Infantile dilated X-linked cardiomyopathy, G4.5 mutations, altered lipids, and ultrastructural malformations of mitochondria in heart, liver, and skeletal muscle.","date":"2002","source":"Laboratory investigation; a journal of technical methods and pathology","url":"https://pubmed.ncbi.nlm.nih.gov/11896212","citation_count":58,"is_preprint":false},{"pmid":"21300850","id":"PMC_21300850","title":"Barth syndrome mutations that cause tafazzin complex lability.","date":"2011","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/21300850","citation_count":57,"is_preprint":false},{"pmid":"27264871","id":"PMC_27264871","title":"Taz1-Shelterin Promotes Facultative Heterochromatin Assembly at Chromosome-Internal Sites Containing Late Replication Origins.","date":"2016","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/27264871","citation_count":56,"is_preprint":false},{"pmid":"23616771","id":"PMC_23616771","title":"Diminished Exercise Capacity and Mitochondrial bc1 Complex Deficiency in Tafazzin-Knockdown Mice.","date":"2013","source":"Frontiers in physiology","url":"https://pubmed.ncbi.nlm.nih.gov/23616771","citation_count":56,"is_preprint":false},{"pmid":"24318983","id":"PMC_24318983","title":"Deletion of the cardiolipin-specific phospholipase Cld1 rescues growth and life span defects in the tafazzin mutant: implications for Barth syndrome.","date":"2013","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24318983","citation_count":55,"is_preprint":false},{"pmid":"19700766","id":"PMC_19700766","title":"Characterization of tafazzin splice variants from humans and fruit flies.","date":"2009","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19700766","citation_count":53,"is_preprint":false},{"pmid":"32234310","id":"PMC_32234310","title":"The Function of Tafazzin, a Mitochondrial Phospholipid-Lysophospholipid Acyltransferase.","date":"2020","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/32234310","citation_count":45,"is_preprint":false},{"pmid":"17429064","id":"PMC_17429064","title":"Fission yeast Taz1 and RPA are synergistically required to prevent rapid telomere loss.","date":"2007","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/17429064","citation_count":45,"is_preprint":false},{"pmid":"30930145","id":"PMC_30930145","title":"The Mitochondrial Transacylase, Tafazzin, Regulates for AML Stemness by Modulating Intracellular Levels of Phospholipids.","date":"2019","source":"Cell stem cell","url":"https://pubmed.ncbi.nlm.nih.gov/30930145","citation_count":43,"is_preprint":false},{"pmid":"25247053","id":"PMC_25247053","title":"Mitochondria-targeted antioxidant prevents cardiac dysfunction induced by tafazzin gene knockdown in cardiac myocytes.","date":"2014","source":"Oxidative medicine and cellular longevity","url":"https://pubmed.ncbi.nlm.nih.gov/25247053","citation_count":43,"is_preprint":false},{"pmid":"30775911","id":"PMC_30775911","title":"Role of Backbone Dynamics in Modulating the Interactions of Disordered Ligands with the TAZ1 Domain of the CREB-Binding Protein.","date":"2019","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30775911","citation_count":42,"is_preprint":false},{"pmid":"15383525","id":"PMC_15383525","title":"Taz1 binding to a fission yeast model telomere: formation of telomeric loops and higher order structures.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15383525","citation_count":40,"is_preprint":false},{"pmid":"28202545","id":"PMC_28202545","title":"The Basis for Acyl Specificity in the Tafazzin Reaction.","date":"2017","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/28202545","citation_count":40,"is_preprint":false},{"pmid":"22633956","id":"PMC_22633956","title":"Taz1 enforces cell-cycle regulation of telomere synthesis.","date":"2012","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/22633956","citation_count":38,"is_preprint":false},{"pmid":"31927328","id":"PMC_31927328","title":"LINC01413/hnRNP-K/ZEB1 Axis Accelerates Cell Proliferation and EMT in Colorectal Cancer via Inducing YAP1/TAZ1 Translocation.","date":"2019","source":"Molecular therapy. Nucleic acids","url":"https://pubmed.ncbi.nlm.nih.gov/31927328","citation_count":38,"is_preprint":false},{"pmid":"15154850","id":"PMC_15154850","title":"The CBP/p300 TAZ1 domain in its native state is not a binding partner of MDM2.","date":"2004","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/15154850","citation_count":37,"is_preprint":false},{"pmid":"29694924","id":"PMC_29694924","title":"Loss of tafazzin results in decreased myoblast differentiation in C2C12 cells: A myoblast model of Barth syndrome and cardiolipin deficiency.","date":"2018","source":"Biochimica et biophysica acta. Molecular and cell biology of lipids","url":"https://pubmed.ncbi.nlm.nih.gov/29694924","citation_count":35,"is_preprint":false},{"pmid":"32665401","id":"PMC_32665401","title":"Tafazzin deficiency impairs CoA-dependent oxidative metabolism in cardiac mitochondria.","date":"2020","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/32665401","citation_count":33,"is_preprint":false},{"pmid":"29557170","id":"PMC_29557170","title":"Substantial Decrease in Plasmalogen in the Heart Associated with Tafazzin Deficiency.","date":"2018","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/29557170","citation_count":33,"is_preprint":false},{"pmid":"20348225","id":"PMC_20348225","title":"Tafazzin knockdown causes hypertrophy of neonatal ventricular myocytes.","date":"2010","source":"American journal of physiology. Heart and circulatory physiology","url":"https://pubmed.ncbi.nlm.nih.gov/20348225","citation_count":32,"is_preprint":false},{"pmid":"18160711","id":"PMC_18160711","title":"Recombination-based telomere maintenance is dependent on Tel1-MRN and Rap1 and inhibited by telomerase, Taz1, and Ku in fission yeast.","date":"2007","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/18160711","citation_count":31,"is_preprint":false},{"pmid":"28515468","id":"PMC_28515468","title":"Cardiolipin content, linoleic acid composition, and tafazzin expression in response to skeletal muscle overload and unload stimuli.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28515468","citation_count":29,"is_preprint":false},{"pmid":"23997105","id":"PMC_23997105","title":"Tafazzin knockdown interrupts cell cycle progression in cultured neonatal ventricular fibroblasts.","date":"2013","source":"American journal of physiology. Heart and circulatory physiology","url":"https://pubmed.ncbi.nlm.nih.gov/23997105","citation_count":29,"is_preprint":false},{"pmid":"24587349","id":"PMC_24587349","title":"Optimization and in vivo toxicity evaluation of G4.5 PAMAM dendrimer-risperidone complexes.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24587349","citation_count":29,"is_preprint":false},{"pmid":"31444868","id":"PMC_31444868","title":"SERCA2a tyrosine nitration coincides with impairments in maximal SERCA activity in left ventricles from tafazzin-deficient mice.","date":"2019","source":"Physiological reports","url":"https://pubmed.ncbi.nlm.nih.gov/31444868","citation_count":28,"is_preprint":false},{"pmid":"31647997","id":"PMC_31647997","title":"TAZ encodes tafazzin, a transacylase essential for cardiolipin formation and central to the etiology of Barth syndrome.","date":"2019","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/31647997","citation_count":27,"is_preprint":false},{"pmid":"33096711","id":"PMC_33096711","title":"Tafazzin Mutation Affecting Cardiolipin Leads to Increased Mitochondrial Superoxide Anions and Mitophagy Inhibition in Barth Syndrome.","date":"2020","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/33096711","citation_count":27,"is_preprint":false},{"pmid":"30055293","id":"PMC_30055293","title":"Aberrant cardiolipin metabolism is associated with cognitive deficiency and hippocampal alteration in tafazzin knockdown mice.","date":"2018","source":"Biochimica et biophysica acta. Molecular basis of disease","url":"https://pubmed.ncbi.nlm.nih.gov/30055293","citation_count":27,"is_preprint":false},{"pmid":"29777197","id":"PMC_29777197","title":"The transition state structure for binding between TAZ1 of CBP and the disordered Hif-1α CAD.","date":"2018","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/29777197","citation_count":26,"is_preprint":false},{"pmid":"28489874","id":"PMC_28489874","title":"Tafazzin (TAZ) promotes the tumorigenicity of cervical cancer cells and inhibits apoptosis.","date":"2017","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/28489874","citation_count":25,"is_preprint":false},{"pmid":"32403321","id":"PMC_32403321","title":"Biotin-Decorated PAMAM G4.5 Dendrimer Nanoparticles to Enhance the Delivery, Anti-Proliferative, and Apoptotic Effects of Chemotherapeutic Drug in Cancer Cells.","date":"2020","source":"Pharmaceutics","url":"https://pubmed.ncbi.nlm.nih.gov/32403321","citation_count":25,"is_preprint":false},{"pmid":"36400945","id":"PMC_36400945","title":"Beneficial effects of SS-31 peptide on cardiac mitochondrial dysfunction in tafazzin knockdown mice.","date":"2022","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/36400945","citation_count":24,"is_preprint":false},{"pmid":"26496965","id":"PMC_26496965","title":"PAMAM G4.5-chlorin e6 dendrimeric nanoparticles for enhanced photodynamic effects.","date":"2015","source":"Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology","url":"https://pubmed.ncbi.nlm.nih.gov/26496965","citation_count":23,"is_preprint":false},{"pmid":"7990135","id":"PMC_7990135","title":"Transmembrane signaling. Mutational analysis of the cytoplasmic linker region of Taz1-1, a Tar-EnvZ chimeric receptor in Escherichia coli.","date":"1994","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/7990135","citation_count":23,"is_preprint":false},{"pmid":"24342716","id":"PMC_24342716","title":"Tafazzin splice variants and mutations in Barth syndrome.","date":"2013","source":"Molecular genetics and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/24342716","citation_count":22,"is_preprint":false},{"pmid":"28707474","id":"PMC_28707474","title":"Native Hydrophobic Binding Interactions at the Transition State for Association between the TAZ1 Domain of CBP and the Disordered TAD-STAT2 Are Not a Requirement.","date":"2017","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/28707474","citation_count":22,"is_preprint":false},{"pmid":"11735032","id":"PMC_11735032","title":"A novel intronic mutation of the TAZ ( G4.5) gene in a patient with Barth syndrome: creation of a 5' splice donor site with variant GC consensus and elongation of the upstream exon.","date":"2001","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11735032","citation_count":22,"is_preprint":false},{"pmid":"32456129","id":"PMC_32456129","title":"Role of Tafazzin in Mitochondrial Function, Development and Disease.","date":"2020","source":"Journal of developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/32456129","citation_count":21,"is_preprint":false},{"pmid":"28096402","id":"PMC_28096402","title":"Establishment of expression-state boundaries by Rif1 and Taz1 in fission yeast.","date":"2017","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/28096402","citation_count":21,"is_preprint":false},{"pmid":"15499385","id":"PMC_15499385","title":"Complex expression pattern of the Barth syndrome gene product tafazzin in human cell lines and murine tissues.","date":"2004","source":"Biochemistry and cell biology = Biochimie et biologie cellulaire","url":"https://pubmed.ncbi.nlm.nih.gov/15499385","citation_count":21,"is_preprint":false},{"pmid":"31603701","id":"PMC_31603701","title":"A critical appraisal of the tafazzin knockdown mouse model of Barth syndrome: what have we learned about pathogenesis and potential treatments?","date":"2019","source":"American journal of physiology. Heart and circulatory physiology","url":"https://pubmed.ncbi.nlm.nih.gov/31603701","citation_count":21,"is_preprint":false},{"pmid":"32123067","id":"PMC_32123067","title":"Investigations of the underlying mechanisms of HIF-1α and CITED2 binding to TAZ1.","date":"2020","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/32123067","citation_count":20,"is_preprint":false},{"pmid":"33289076","id":"PMC_33289076","title":"PAMAM G4.5 dendrimers for targeted delivery of ferulic acid and paclitaxel to overcome P-glycoprotein-mediated multidrug resistance.","date":"2020","source":"Biotechnology and bioengineering","url":"https://pubmed.ncbi.nlm.nih.gov/33289076","citation_count":20,"is_preprint":false},{"pmid":"36917259","id":"PMC_36917259","title":"Genetic modifiers modulate phenotypic expression of tafazzin deficiency in a mouse model of Barth syndrome.","date":"2023","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/36917259","citation_count":19,"is_preprint":false},{"pmid":"30741413","id":"PMC_30741413","title":"Suppression of Tafazzin promotes thyroid cancer apoptosis via activating the JNK signaling pathway and enhancing INF2-mediated mitochondrial fission.","date":"2019","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/30741413","citation_count":18,"is_preprint":false},{"pmid":"25941633","id":"PMC_25941633","title":"Structural and functional analyses of Barth syndrome-causing mutations and alternative splicing in the tafazzin acyltransferase domain.","date":"2015","source":"Meta gene","url":"https://pubmed.ncbi.nlm.nih.gov/25941633","citation_count":18,"is_preprint":false},{"pmid":"31056533","id":"PMC_31056533","title":"Downregulation of miR-125b promotes resistance of glioma cells to TRAIL through overexpression of Tafazzin which is a mitochondrial protein.","date":"2019","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/31056533","citation_count":18,"is_preprint":false},{"pmid":"29405656","id":"PMC_29405656","title":"Drosophila tafazzin mutants have impaired exercise capacity.","date":"2018","source":"Physiological reports","url":"https://pubmed.ncbi.nlm.nih.gov/29405656","citation_count":17,"is_preprint":false},{"pmid":"26114544","id":"PMC_26114544","title":"Mouse Tafazzin Is Required for Male Germ Cell Meiosis and Spermatogenesis.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26114544","citation_count":17,"is_preprint":false},{"pmid":"26692032","id":"PMC_26692032","title":"Acquired deficiency of tafazzin in the adult heart: Impact on mitochondrial function and response to cardiac injury.","date":"2015","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/26692032","citation_count":16,"is_preprint":false},{"pmid":"30389594","id":"PMC_30389594","title":"Cardiac mitochondrial structure and function in tafazzin-knockdown mice.","date":"2018","source":"Mitochondrion","url":"https://pubmed.ncbi.nlm.nih.gov/30389594","citation_count":15,"is_preprint":false},{"pmid":"34979560","id":"PMC_34979560","title":"A new murine model of Barth syndrome neutropenia links TAFAZZIN deficiency to increased ER stress-induced apoptosis.","date":"2022","source":"Blood advances","url":"https://pubmed.ncbi.nlm.nih.gov/34979560","citation_count":15,"is_preprint":false},{"pmid":"30632304","id":"PMC_30632304","title":"Increased Dynamin-Related Protein 1-Dependent Mitochondrial Fission Contributes to High-Fat-Diet-Induced Cardiac Dysfunction and Insulin Resistance by Elevating Tafazzin in Mouse Hearts.","date":"2019","source":"Molecular nutrition & food research","url":"https://pubmed.ncbi.nlm.nih.gov/30632304","citation_count":15,"is_preprint":false},{"pmid":"32242581","id":"PMC_32242581","title":"Competitive binding of HIF-1α and CITED2 to the TAZ1 domain of CBP from molecular simulations.","date":"2020","source":"Physical chemistry chemical physics : PCCP","url":"https://pubmed.ncbi.nlm.nih.gov/32242581","citation_count":15,"is_preprint":false},{"pmid":"34019639","id":"PMC_34019639","title":"Tafazzin Deficiency Reduces Basal Insulin Secretion and Mitochondrial Function in Pancreatic Islets From Male Mice.","date":"2021","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/34019639","citation_count":14,"is_preprint":false},{"pmid":"29796387","id":"PMC_29796387","title":"Decreasing cytosolic translation is beneficial to yeast and human Tafazzin-deficient cells.","date":"2018","source":"Microbial cell (Graz, Austria)","url":"https://pubmed.ncbi.nlm.nih.gov/29796387","citation_count":14,"is_preprint":false},{"pmid":"20303308","id":"PMC_20303308","title":"Gonadal mosaicism of a TAZ (G4.5) mutation in a Japanese family with Barth syndrome and left ventricular noncompaction.","date":"2010","source":"Molecular genetics and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/20303308","citation_count":14,"is_preprint":false},{"pmid":"29129703","id":"PMC_29129703","title":"Identification of novel mitochondrial localization signals in human Tafazzin, the cause of the inherited cardiomyopathic disorder Barth syndrome.","date":"2017","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/29129703","citation_count":13,"is_preprint":false},{"pmid":"31719609","id":"PMC_31719609","title":"Characterization of the dynamics and the conformational entropy in the binding between TAZ1 and CTAD-HIF-1α.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/31719609","citation_count":12,"is_preprint":false},{"pmid":"34494285","id":"PMC_34494285","title":"The lipid environment modulates cardiolipin and phospholipid constitution in wild type and tafazzin-deficient cells.","date":"2021","source":"Journal of inherited metabolic disease","url":"https://pubmed.ncbi.nlm.nih.gov/34494285","citation_count":12,"is_preprint":false},{"pmid":"30639735","id":"PMC_30639735","title":"Tafazzin-dependent cardiolipin composition in C6 glioma cells correlates with changes in mitochondrial and cellular functions, and cellular proliferation.","date":"2019","source":"Biochimica et biophysica acta. Molecular and cell biology of lipids","url":"https://pubmed.ncbi.nlm.nih.gov/30639735","citation_count":12,"is_preprint":false},{"pmid":"17621587","id":"PMC_17621587","title":"Evaluation of tafazzin as candidate for dilated cardiomyopathy in Irish wolfhounds.","date":"2007","source":"The Journal of heredity","url":"https://pubmed.ncbi.nlm.nih.gov/17621587","citation_count":12,"is_preprint":false},{"pmid":"12032589","id":"PMC_12032589","title":"Novel missense mutation (R94S) in the TAZ ( G4.5) gene in a Japanese patient with Barth syndrome.","date":"2002","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/12032589","citation_count":12,"is_preprint":false},{"pmid":"29325722","id":"PMC_29325722","title":"Effects of siRNA-dependent knock-down of cardiolipin synthase and tafazzin on mitochondria and proliferation of glioma cells.","date":"2018","source":"Biochimica et biophysica acta. Molecular and cell biology of lipids","url":"https://pubmed.ncbi.nlm.nih.gov/29325722","citation_count":10,"is_preprint":false},{"pmid":"31686855","id":"PMC_31686855","title":"Restoration of miR-26b expression partially reverses the cisplatin resistance of NSCLC by targeting tafazzin.","date":"2019","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/31686855","citation_count":10,"is_preprint":false},{"pmid":"34767647","id":"PMC_34767647","title":"Tafazzin deficiency impairs mitochondrial metabolism and function of lipopolysaccharide activated B lymphocytes in mice.","date":"2021","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/34767647","citation_count":9,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":45743,"output_tokens":5752,"usd":0.111755,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":14506,"output_tokens":6023,"usd":0.111552,"stage2_stop_reason":"end_turn"},"total_usd":0.223307,"stage1_batch_id":"msgbatch_017qqVz33Ga63SCDwzb35XPb","stage2_batch_id":"msgbatch_01Scr2Ei9x4HJMiRGxwrmvLK","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1996,\n      \"finding\": \"Mutations in the X-linked gene G4.5 (encoding tafazzin proteins produced by alternative splicing) cause Barth syndrome; stop codon mutations interrupt translation of most tafazzin isoforms, establishing G4.5/TAFAZZIN as the disease locus.\",\n      \"method\": \"Mutation analysis (DNA sequencing identifying stop codon mutations) in Barth syndrome patients\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct mutation identification in multiple patients, replicated across subsequent studies\",\n      \"pmids\": [\"8630491\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Drosophila tafazzin functions as a CoA-independent, acyl-specific phospholipid-lysophospholipid transacylase, catalyzing transfer of acyl groups (preferentially linoleoyl) between cardiolipin and phosphatidylcholine without utilizing CoA or acyl-CoA as substrates; the highest rate is for the phosphatidylcholine–cardiolipin transacylation.\",\n      \"method\": \"In vitro transacylase assay using baculovirus-expressed Drosophila tafazzin and affinity-purified MBP-tafazzin fusion protein; radiolabeled substrate transfer; substrate specificity profiling\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct in vitro enzymatic reconstitution with purified protein, replicated in multiple subsequent studies\",\n      \"pmids\": [\"17082194\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Yeast taz1Δ (null mutation in the TAFAZZIN homolog) shows reduced total cardiolipin, accumulation of monolyso-CL, loss of unsaturated CL species (C18:1 and C16:1), and increased de novo CL synthesis without upregulation of CL structural genes CRD1 or PGS1, demonstrating tafazzin's role in cardiolipin remodeling and acyl composition.\",\n      \"method\": \"Yeast genetic model (taz1Δ null mutant); lipid analysis by mass spectrometry/chromatography; growth assays\",\n      \"journal\": \"Molecular microbiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean genetic KO with defined biochemical phenotype, replicated across multiple labs\",\n      \"pmids\": [\"14651618\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Yeast Taz1 (tafazzin ortholog) is an outer mitochondrial membrane protein exposed to the intermembrane space (IMS); its import into mitochondria depends on the TOM receptor Tom5 and the small Tim IMS proteins, but is independent of the SAM complex. TAZ1 deletion destabilizes respiratory chain supercomplexes III2IV2, causing selective release of complex IV monomer and impairing its assembly into supercomplexes.\",\n      \"method\": \"Subcellular fractionation, protease protection assay, import assays with Tom5/Tim mutants; BN-PAGE supercomplex analysis; radiolabeled subunit import into taz1Δ mitochondria\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple orthogonal methods (fractionation, import assays, BN-PAGE), single lab but rigorous\",\n      \"pmids\": [\"16135531\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Yeast tafazzin (Taz1p) physically assembles into several distinct protein complexes; ATP synthase and AAC2 are identified in separate stable Taz1p complexes by co-immunoprecipitation/MS. The largest Taz1p complex requires both assembled ATP synthase and cardiolipin. Loss of Taz1p alters cristae morphology similar to ATP synthase oligomer mutants without affecting ATP synthase complex assembly.\",\n      \"method\": \"Co-immunoprecipitation, mass spectrometry (interactome), BN-PAGE, electron microscopy of Δtaz1 mitochondria\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal co-IP with MS identification plus morphological and biochemical validation, single lab but multiple orthogonal methods\",\n      \"pmids\": [\"18799610\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Tafazzin's transacylation specificity is determined by the physical state (lipid phase) of its substrates rather than intrinsic enzyme acyl selectivity; tetralinoleoyl-cardiolipin forms only under conditions favoring the inverted hexagonal phase, and substantial transacylation occurs only in non-bilayer lipid aggregates. In isolated mitochondria, <1% of lipids participate in transacylation, suggesting tafazzin acts at privileged non-bilayer lipid domains.\",\n      \"method\": \"In vitro transacylation assay with isolated tafazzin; 31P-NMR characterization of lipid phase; mass spectrometry of molecular species; isolated mitochondria transacylation measurement\",\n      \"journal\": \"Nature chemical biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstitution with purified enzyme plus structural (NMR) and MS characterization; multiple orthogonal methods in one rigorous study\",\n      \"pmids\": [\"22941046\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Among human tafazzin splice isoforms, only full-length (FL) and the exon-5-deleted (Δ5) isoforms have transacylase activity in vitro and are able to restore normal cardiolipin pattern and respiratory activity in tafazzin-deficient flies; both localize to mitochondria in HeLa cells, but Δ5 is more integrated into the hydrophobic membrane core. Human tafazzin expression in flies generates cardiolipin with a Drosophila (not human) acyl pattern, indicating acyl specificity is not encoded by tafazzin itself.\",\n      \"method\": \"Expression of isoforms in HeLa/293T and Drosophila; transacylase activity assays; cardiolipin profiling by MS; subcellular fractionation; proteinase K/alkali treatment for topology\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — enzymatic reconstitution, in vivo complementation, topology experiments, MS; multiple orthogonal methods\",\n      \"pmids\": [\"19700766\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"The acyl specificity of the tafazzin reaction results from the physical properties (thermodynamic/packing) of the lipid environment rather than intrinsic enzyme-level kinetic specificity; forward and reverse transacylation rates toward equilibrium are similar across different acyl groups, and tafazzin creates an equilibrium distribution of acyl groups.\",\n      \"method\": \"In vitro transacylation kinetics with yeast tafazzin; comparison of initial rates to equilibrium states across acyl groups; MS quantification of cardiolipin molecular species\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — rigorous in vitro enzymatic analysis with kinetic and thermodynamic dissection, single lab\",\n      \"pmids\": [\"28202545\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Eighteen of 21 tested Barth syndrome missense mutations in tafazzin fail to functionally replace endogenous Taz1p in yeast. Four BTHS mutant tafazzins are degraded by the IMS AAA (i-AAA) protease due to misfolding; paradoxically these assemble into normal-appearing complexes that are inherently unstable and aggregate upon disassembly. Loss of i-AAA protease partially rescues mutant function.\",\n      \"method\": \"Yeast BTHS mutant panel; functional complementation assays; BN-PAGE complex analysis; i-AAA protease deletion epistasis; protein stability assays\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — systematic panel of 21 mutations with multiple orthogonal functional and biochemical readouts, single lab\",\n      \"pmids\": [\"21300850\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"TAZ/tafazzin-mediated cardiolipin remodeling is selectively required for the initiation of mitophagy (mitophagosome biogenesis) but not for other autophagic processes; TAZ deficiency in mouse embryonic fibroblasts causes defective mitophagy, impaired oxidative phosphorylation, and severe oxidative stress.\",\n      \"method\": \"Doxycycline-inducible Taz knockdown in primary MEFs; autophagy flux assays; mitophagy-specific assays; oxidative phosphorylation measurements\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean inducible KD with specific mitophagy phenotype readout, single lab, two methods\",\n      \"pmids\": [\"25919711\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Deletion of the CL-specific phospholipase Cld1 rescues growth, lifespan, and respiratory defects of the yeast taz1Δ mutant, demonstrating that the decreased CL/MLCL ratio (not deficiency in unsaturated CL) is the primary cause of physiological defects in tafazzin-deficient cells.\",\n      \"method\": \"Genetic epistasis (cld1Δ taz1Δ double mutant); growth and lifespan assays; respiratory measurements; lipid analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean genetic epistasis with defined biochemical and physiological phenotypes, multiple readouts\",\n      \"pmids\": [\"24318983\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Loss of tafazzin (taz1Δ) in yeast causes increased reactive oxygen species (protein carbonylation) specifically during respiratory growth on ethanol; supplementation with oleic acid rescues ethanol sensitivity and reduces oxidative stress in taz1Δ but not crd1Δ, suggesting oleoyl-CL or oleoyl-MLCL mediates this protection.\",\n      \"method\": \"Yeast taz1Δ and crd1Δ mutants; protein carbonylation assay (ROS marker); growth assays; oleic acid supplementation rescue\",\n      \"journal\": \"Molecular microbiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO with defined biochemical phenotype, rescue experiment, single lab\",\n      \"pmids\": [\"18430085\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Aim24, an inner mitochondrial membrane protein interacting with the MICOS complex, is required to maintain tafazzin levels; loss of Aim24 drastically reduces tafazzin protein and alters cardiolipin composition similarly to tafazzin mutants, placing tafazzin functionally downstream of the Aim24–MICOS axis.\",\n      \"method\": \"Co-immunoprecipitation (Aim24–MICOS interaction); protein level analysis; cardiolipin composition by MS in aim24 mutants\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP plus lipid phenotyping, single lab, two orthogonal methods\",\n      \"pmids\": [\"24714493\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Two distinct peptide sequences within human tafazzin independently direct the protein to mitochondria; these mitochondrial localization signals are not within predicted enzymatic clefts, implying some BTHS mutations may disrupt localization independently of transacylase activity.\",\n      \"method\": \"Sequential TAZ peptide–eGFP fusion protein expression in H9c2 cells; confocal microscopy co-localization with organellar markers; CRISPR TAZ knockout cell lines\",\n      \"journal\": \"Journal of molecular and cellular cardiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct localization by live-cell imaging with functional validation in KO background, single lab\",\n      \"pmids\": [\"29129703\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Tafazzin deficiency causes a substantial decrease in plasmenylcholine (plasmalogen) in the heart, in addition to reduced CL and accumulated MLCL; purified tafazzin catalyzes transacylation between lyso-plasmenylcholine/plasmenylcholine and CL/MLCL, establishing plasmenylcholine as a tafazzin substrate for CL remodeling.\",\n      \"method\": \"31P-NMR lipid quantification in TAZ-KD mouse hearts; in vitro transacylation assay with purified tafazzin and plasmalogen substrates; Western blot for Far1\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with purified enzyme plus in vivo lipid phenotyping by NMR, single lab, two orthogonal methods\",\n      \"pmids\": [\"29557170\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Tafazzin deficiency in mouse hearts causes deficiencies in mitochondrial CoA and shifts in the acyl-CoA profile that impair fatty acid and pyruvate oxidation (40–60% lower); exogenous CoA partially rescues these oxidation defects, implicating dysregulation of CoA-dependent intermediary metabolism rather than primary respiratory chain defects as the bioenergetic consequence of tafazzin deficiency.\",\n      \"method\": \"Taz-shRNA knockdown mice; mitochondrial substrate oxidation assays; CoA metabolite profiling by LC-MS; CoA supplementation rescue experiments\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean KD model, substrate oxidation assays, metabolomics, rescue experiment; single lab\",\n      \"pmids\": [\"32665401\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Tafazzin (TAZ) is necessary for growth and viability of AML cells (identified by CRISPR screen); TAZ inhibition reduces AML stemness and increases differentiation in vitro and in vivo by decreasing cardiolipin and altering global phospholipid levels (including phosphatidylserine), which modulates toll-like receptor (TLR) signaling.\",\n      \"method\": \"CRISPR screen; genetic TAZ inhibition in AML cells in vitro and xenograft in vivo; phospholipid profiling; TLR signaling pathway analysis\",\n      \"journal\": \"Cell stem cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — CRISPR KO with defined cellular phenotype plus pathway placement via lipid profiling and TLR signaling, single lab\",\n      \"pmids\": [\"30930145\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Mouse tafazzin (Taz) is required for male germ cell meiosis; Taz knockout chimera testes show disruption of spermatocyte progression past the pachytene stage, elevated DNA double-strand damage, and increased endogenous retrotransposon activity, revealing a role for tafazzin in maintaining genome integrity during meiosis.\",\n      \"method\": \"Taz knockout mouse chimeras; histological analysis of testes; DNA damage markers (γH2AX); retrotransposon expression; in vitro germ cell differentiation from KO ES cells\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO with defined meiotic phenotype and molecular markers, single lab\",\n      \"pmids\": [\"26114544\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Tafazzin knockdown in lymphoblasts from Barth syndrome patients destabilizes the respiratory supercomplex I+III2+IVn (respirasome) and reduces individual complexes I and IV, complex V, and supercomplexes I+III and III+IV; complex III amount and complex II are unaffected. Mitochondrial mass increases as a compensatory response, and the type II (mitochondrial) apoptosis pathway is blocked because mitochondria cannot bind active caspase-8.\",\n      \"method\": \"Immortalized patient lymphoblasts; BN-PAGE supercomplex analysis; electron microscopy; citrate synthase activity; flow cytometry for apoptosis/caspase-8 binding\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — patient-derived cells, multiple orthogonal methods; single lab\",\n      \"pmids\": [\"23523468\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Distinct effects of tafazzin deletion on mitochondrial ultrastructure depend on cellular differentiation state: tafazzin deficiency affects cardiolipin in all mitochondria, but significant structural alterations (inner membrane remodeling and aggregation) occur only after specific differentiation, as shown in cardiomyocytes vs. embryonic stem cells and in different Drosophila tissues.\",\n      \"method\": \"Electron tomography of tafazzin-deleted mouse cardiomyocytes, embryonic stem cells, and Drosophila tissues; cardiolipin profiling\",\n      \"journal\": \"Mitochondrion\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — electron tomography (structural method) with comparative cellular context; single lab\",\n      \"pmids\": [\"19114128\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"In vivo treatment with the mitochondria-targeted peptide SS-31 improves mitochondrial respiratory capacity and promotes supercomplex organization in tafazzin-knockdown mouse cardiac mitochondria without affecting the MLCL/CL ratio, suggesting SS-31 acts on respiratory chain function independently of direct CL modification.\",\n      \"method\": \"In vivo SS-31 administration in TazKD mice; MALDI-TOF/MS lipid profiling; mitochondrial respiration assays; BN-PAGE supercomplex analysis\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo intervention with functional and lipid readouts; single lab\",\n      \"pmids\": [\"36400945\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Tafazzin deletion in C2C12 myoblasts (TAZ-KO) causes accumulation of monolyso-CL, decreased mitochondrial respiration, increased mitochondrial ROS, and impaired myocyte differentiation, linking defective CL remodeling to skeletal myoblast differentiation defects.\",\n      \"method\": \"CRISPR-generated stable tafazzin KO C2C12 cell line; cardiolipin profiling; mitochondrial respiration (Seahorse); ROS measurement; differentiation assays\",\n      \"journal\": \"Biochimica et biophysica acta. Molecular and cell biology of lipids\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — CRISPR KO with defined biochemical and differentiation phenotypes; single lab\",\n      \"pmids\": [\"29694924\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"TAFAZZIN-deficient neutrophil progenitors (in KO mice and ER-Hoxb8 system) show increased sensitivity to ER stress-mediated apoptosis, with transcriptomic upregulation of ER stress markers, providing a mechanistic link between tafazzin loss and neutrophil vulnerability.\",\n      \"method\": \"TAFAZZIN KO mice; ER-Hoxb8 conditional immortalization system; transcriptomic analysis; apoptosis assays with ER stress inducers\",\n      \"journal\": \"Blood advances\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — two model systems, transcriptomics plus functional apoptosis assay; single lab\",\n      \"pmids\": [\"34979560\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"Tafazzin is a mitochondrial CoA-independent phospholipid-lysophospholipid transacylase that remodels cardiolipin by exchanging acyl chains between phospholipids (preferentially phosphatidylcholine and cardiolipin), with acyl specificity dictated by the physical properties (phase state) of non-bilayer lipid domains rather than by intrinsic enzymatic selectivity; it localizes to the mitochondrial membrane via two distinct targeting peptides, assembles into complexes with ATP synthase and the adenine nucleotide carrier, and its loss causes accumulation of monolyso-cardiolipin, destabilization of respiratory supercomplexes, impaired oxidative phosphorylation, increased ROS, defective mitophagy, and—in vivo—cardiomyopathy, skeletal myopathy, and neutropenia characteristic of Barth syndrome.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"Tafazzin is a mitochondrial CoA-independent phospholipid–lysophospholipid transacylase that remodels cardiolipin, and its loss causes the X-linked disorder Barth syndrome [#0, #1]. The enzyme transfers acyl chains between phospholipids—preferentially exchanging linoleoyl groups between phosphatidylcholine and cardiolipin, and also drawing on plasmenylcholine as a donor—without using CoA or acyl-CoA [#1, #14]. Rather than encoding intrinsic acyl selectivity, tafazzin generates an equilibrium distribution of acyl species whose final composition is dictated by the physical/phase state of its lipid substrates, acting preferentially at non-bilayer lipid domains [#5, #7]; consistent with this, human tafazzin expressed in flies produces a Drosophila acyl pattern [#6]. Loss of tafazzin reduces total cardiolipin and causes accumulation of monolyso-cardiolipin, and it is this decreased CL/MLCL ratio—not the deficit in unsaturated CL—that drives the physiological defects, since deleting the CL-specific phospholipase Cld1 rescues taz-null cells [#2, #10]. Tafazzin localizes to mitochondria via two independent targeting peptides and is imported through the TOM/small-Tim pathway to face the intermembrane space [#3, #13]; it assembles into distinct complexes with ATP synthase and the adenine nucleotide carrier AAC2 [#4]. Functionally, tafazzin remodeling is required to stabilize respiratory chain supercomplexes (respirasomes), and its loss destabilizes complex IV-containing supercomplexes, impairs oxidative phosphorylation, increases ROS, and disrupts cristae architecture in a differentiation-dependent manner [#3, #18, #19]. Downstream consequences include defective mitophagy initiation, dysregulated CoA-dependent fatty acid and pyruvate oxidation, and impaired myocyte differentiation [#9, #15, #21]. Disease-relevant phenotypes trace to these defects: most Barth syndrome missense mutants fail to function and are degraded by the i-AAA protease [#8], and tafazzin loss confers cardiac, skeletal-muscle, and neutrophil vulnerabilities, the last via heightened sensitivity to ER stress-mediated apoptosis [#21, #22].\",\n  \"teleology\": [\n    {\n      \"year\": 1996,\n      \"claim\": \"Established TAFAZZIN (G4.5) as the genetic cause of a human disease, defining the disease locus before any molecular function was known.\",\n      \"evidence\": \"Mutation analysis identifying stop-codon mutations in Barth syndrome patients\",\n      \"pmids\": [\"8630491\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not reveal the biochemical function of the encoded protein\", \"Functional consequences of individual splice isoforms unresolved\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Linked tafazzin to cardiolipin biology by showing a null mutant accumulates monolyso-CL and loses unsaturated CL species, defining its role in CL acyl remodeling rather than de novo synthesis.\",\n      \"evidence\": \"Yeast taz1Δ null mutant with MS lipid profiling and growth assays\",\n      \"pmids\": [\"14651618\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not establish the enzymatic mechanism directly\", \"Did not determine acyl-chain donor specificity\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Located tafazzin topologically and connected its loss to respiratory supercomplex integrity, the first link between CL remodeling and OXPHOS assembly.\",\n      \"evidence\": \"Subcellular fractionation, protease protection, TOM/Tim import assays, and BN-PAGE supercomplex analysis in yeast\",\n      \"pmids\": [\"16135531\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which CL remodeling stabilizes supercomplexes not defined\", \"Did not address mammalian topology\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Defined the enzymatic activity directly: tafazzin is a CoA-independent, acyl-specific phospholipid–lysophospholipid transacylase favoring PC–CL transfer.\",\n      \"evidence\": \"In vitro transacylase assay with purified baculovirus-expressed Drosophila tafazzin and radiolabeled substrate transfer\",\n      \"pmids\": [\"17082194\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Source of acyl-chain specificity not yet explained\", \"Did not test plasmalogen or other phospholipid donors\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Mapped tafazzin into discrete physical complexes with ATP synthase and AAC2 and linked its loss to cristae morphology, positioning it within the mitochondrial membrane architecture machinery.\",\n      \"evidence\": \"Co-IP/MS interactome, BN-PAGE, and electron microscopy of Δtaz1 yeast mitochondria\",\n      \"pmids\": [\"18799610\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry and function of each complex not resolved\", \"Whether complexes reflect catalytic substrate channeling unknown\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Connected tafazzin loss to oxidative stress and identified a specific protective lipid species, refining which CL/MLCL derivatives matter physiologically.\",\n      \"evidence\": \"Protein carbonylation in taz1Δ vs crd1Δ yeast with oleic-acid rescue\",\n      \"pmids\": [\"18430085\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct demonstration that oleoyl-CL/MLCL is the protective species not shown\", \"Relevance to mammalian ROS phenotype untested\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Resolved which human splice isoforms are catalytically competent and showed acyl specificity is host-encoded, not enzyme-intrinsic.\",\n      \"evidence\": \"Isoform expression in HeLa/293T and Drosophila, transacylase assays, CL profiling, and topology experiments\",\n      \"pmids\": [\"19700766\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Why exon-5 deletion alters membrane integration mechanistically unclear\", \"Physiological roles of inactive isoforms unknown\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Explained how Barth missense mutations cause disease: most are non-functional, and a subset is degraded by the i-AAA protease due to misfolding.\",\n      \"evidence\": \"Systematic yeast complementation of 21 BTHS mutants with BN-PAGE and i-AAA protease epistasis\",\n      \"pmids\": [\"21300850\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of misfolding not defined\", \"Whether the same degradation pathway operates in human cells untested\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Provided the physical explanation for acyl specificity—lipid phase state, not enzyme kinetics, drives tetralinoleoyl-CL formation at non-bilayer domains.\",\n      \"evidence\": \"In vitro transacylation with 31P-NMR lipid-phase characterization and MS species analysis\",\n      \"pmids\": [\"22941046\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the privileged non-bilayer domains in vivo not defined\", \"How tafazzin is recruited to these domains unknown\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Demonstrated genetically that the low CL/MLCL ratio, not loss of unsaturated CL, is the proximal cause of physiological defects.\",\n      \"evidence\": \"cld1Δ taz1Δ double-mutant epistasis with growth, lifespan, respiration, and lipid readouts in yeast\",\n      \"pmids\": [\"24318983\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis of MLCL toxicity not defined\", \"Whether Cld1 deletion rescues mammalian phenotypes untested\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Quantified the supercomplex defect in patient cells and linked tafazzin loss to a block in mitochondrial apoptosis via impaired caspase-8 binding.\",\n      \"evidence\": \"BN-PAGE, EM, citrate synthase, and flow cytometry in Barth patient lymphoblasts\",\n      \"pmids\": [\"23523468\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism connecting CL remodeling to caspase-8 recruitment unresolved\", \"Single lab, patient-derived cells only\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Placed tafazzin downstream of the Aim24–MICOS axis, identifying an upstream determinant of tafazzin protein levels.\",\n      \"evidence\": \"Co-IP and CL profiling in aim24 mutant yeast\",\n      \"pmids\": [\"24714493\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How Aim24/MICOS stabilizes tafazzin mechanistically unknown\", \"No mammalian validation\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Identified mitophagy initiation as a selective process requiring CL remodeling, distinguishing it from bulk autophagy.\",\n      \"evidence\": \"Inducible Taz knockdown in primary MEFs with autophagy/mitophagy flux and OXPHOS assays\",\n      \"pmids\": [\"25919711\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular role of remodeled CL in mitophagosome biogenesis not defined\", \"Single lab, two methods\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Revealed a non-bioenergetic role in male meiosis and genome integrity, broadening tafazzin's physiological reach.\",\n      \"evidence\": \"Taz KO mouse chimeras with testis histology, γH2AX, retrotransposon expression, and KO ES germ-cell differentiation\",\n      \"pmids\": [\"26114544\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanistic link between CL remodeling and meiotic genome stability unclear\", \"Whether the defect is mitochondrial-autonomous unknown\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Established quantitatively that tafazzin drives acyl groups toward thermodynamic equilibrium rather than imposing kinetic selectivity.\",\n      \"evidence\": \"In vitro kinetic and equilibrium analysis with yeast tafazzin and MS quantification\",\n      \"pmids\": [\"28202545\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How equilibrium tuning produces tissue-specific CL patterns in vivo unresolved\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Mapped two independent mitochondrial targeting peptides outside the catalytic cleft, implying some BTHS mutations may act by disrupting localization rather than catalysis.\",\n      \"evidence\": \"TAZ peptide–eGFP fusions and confocal co-localization in H9c2 cells with CRISPR TAZ-KO controls\",\n      \"pmids\": [\"29129703\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Which disease mutations disrupt localization not directly tested\", \"Relative contribution of each peptide unclear\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Expanded the substrate repertoire by showing plasmenylcholine is a tafazzin donor for CL remodeling and is depleted in deficient hearts.\",\n      \"evidence\": \"31P-NMR lipid quantification in TAZ-KD mouse hearts and in vitro transacylation with purified enzyme and plasmalogen substrates\",\n      \"pmids\": [\"29557170\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological significance of plasmalogen depletion in Barth syndrome unresolved\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Identified tafazzin as a vulnerability in acute myeloid leukemia, linking CL/phospholipid remodeling to stemness via TLR signaling.\",\n      \"evidence\": \"CRISPR screen and genetic TAZ inhibition in AML cells and xenografts with phospholipid and TLR pathway analysis\",\n      \"pmids\": [\"30930145\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct mechanism connecting phosphatidylserine changes to TLR signaling not fully defined\", \"Specificity to AML versus other cancers untested\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Tied CL remodeling defects to skeletal-muscle differentiation, modeling the myopathy component of Barth syndrome.\",\n      \"evidence\": \"CRISPR TAZ-KO C2C12 myoblasts with CL profiling, Seahorse respiration, ROS, and differentiation assays\",\n      \"pmids\": [\"29694924\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism linking respiratory defect to differentiation block unclear\", \"Single cell-line model\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Reframed the bioenergetic defect as dysregulation of CoA-dependent intermediary metabolism, partially rescuable by exogenous CoA.\",\n      \"evidence\": \"Taz-shRNA knockdown mice with substrate oxidation assays, CoA metabolomics, and CoA supplementation\",\n      \"pmids\": [\"32665401\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How CL/MLCL imbalance lowers mitochondrial CoA mechanistically unknown\", \"Relative contribution of CoA defect vs supercomplex defect unresolved\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Provided a candidate therapeutic mechanism: SS-31 restores respiratory function and supercomplex organization independently of correcting the MLCL/CL ratio.\",\n      \"evidence\": \"In vivo SS-31 in TazKD mice with MALDI lipid profiling, respiration, and BN-PAGE\",\n      \"pmids\": [\"36400945\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular target of SS-31 in this context not defined\", \"Durability and disease-modifying effect untested\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Explained neutropenia in Barth syndrome by linking tafazzin loss to ER stress-mediated apoptosis in neutrophil progenitors.\",\n      \"evidence\": \"TAFAZZIN KO mice and ER-Hoxb8 system with transcriptomics and ER stress apoptosis assays\",\n      \"pmids\": [\"34979560\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Connection between mitochondrial CL defect and ER stress signaling not defined\", \"Whether intervention rescues neutrophil numbers untested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How tafazzin is recruited to specific non-bilayer lipid domains in vivo, and how a single equilibrium-driving transacylase produces tissue-specific cardiolipin signatures and the diverse downstream phenotypes (mitophagy, CoA metabolism, ER stress), remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structure of human tafazzin bound to substrate\", \"Mechanism linking CL/MLCL ratio to supercomplex stabilization, mitophagy, and apoptosis not unified\", \"In vivo determinants of acyl-chain specificity per tissue unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [1, 5, 6, 7, 14]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [1, 14]},\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [1, 5, 14]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [3, 6, 13]},\n      {\"term_id\": \"GO:0005635\", \"supporting_discovery_ids\": [3]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [2, 14, 15]},\n      {\"term_id\": \"R-HSA-1852241\", \"supporting_discovery_ids\": [3, 4, 18, 19]},\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [9]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [0, 8]}\n    ],\n    \"complexes\": [\n      \"ATP synthase complex\",\n      \"AAC2 (adenine nucleotide carrier) complex\"\n    ],\n    \"partners\": [\n      \"ATP synthase\",\n      \"AAC2\",\n      \"Aim24\",\n      \"MICOS\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}